These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 6370428

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, van 't Veer MB, Rammeloo JA, de Koning J, van Zanen GE.
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [Abstract] [Full Text] [Related]

  • 3. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E, PETHEMA Group.
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM.
    Cancer; 2004 Mar 15; 100(6):1179-85. PubMed ID: 15022284
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An update of the results of intensive therapy in children with acute lymphoblastic leukemia.
    Pavlovsky S, Sackmann Muriel F, Santarelli MT, Svarch E, Jiménez E, Kohan R, Rosso A.
    Leukemia; 1992 Mar 15; 6 Suppl 2():167-70. PubMed ID: 1578923
    [Abstract] [Full Text] [Related]

  • 13. Daunorubicin, vincristine, and prednisone for remission induction in patients with acute lymphoblastic leukemia in relapse.
    Pavlovsky S, Muriel FS, Eppinger-Helft M, Bustelo P, Garay G, Giuntoli JM, Kvicala R, Divito J, Picón A.
    Cancer Treat Rep; 1983 May 15; 67(5):425-7. PubMed ID: 6573958
    [Abstract] [Full Text] [Related]

  • 14. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H, Kawakami K, Ayukawa H, Akiyoshi K, Kamizono J, Tamai Y, Kinukawa N, Okamura J.
    Med Pediatr Oncol; 2001 Jul 15; 37(1):10-9. PubMed ID: 11466717
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia.
    Sackmann-Muriel F, Svarch E, Eppinger-Helft M, Braier JL, Pavlovsky S, Guman L, Vergara B, Ponzinibbio C, Failace R, Garay GE, Bugnard E, Ojeda FG, De Bellis R, de Sijvarger SR, Saslavsky J.
    Cancer; 1978 Oct 15; 42(4):1730-40. PubMed ID: 101296
    [Abstract] [Full Text] [Related]

  • 19. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S, Balwierz W, Moryl-Bujakowska A, Pawińska K, Luszczyńska A, Balcerska A, Płoszyńska A, Chybicka A, Dobaczewski G, Juszczak K, Wachowiak J, Derwich K, Kowalczyk J, Wiśniewska-Slusarz H, Matysiak M, Krauze A, Pawelec K, Sońta-Jakimczyk D, Tomaszewska R, Wysocki M, Styczyńskii J, Swiatkiewicz V, Polish Pediatric Leukemia/Lymphoma Study Group.
    Przegl Lek; 2006 Oct 15; 63(1):11-4. PubMed ID: 16892892
    [Abstract] [Full Text] [Related]

  • 20. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A, Ishii E, Okamura J, Eguchi H, Yoshida N, Yanai F, Inoue T, Miyake K, Ishihara T, Tsuboi C.
    Med Pediatr Oncol; 1996 Jan 15; 26(1):10-9. PubMed ID: 7494507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.